News Hub | News Direct

Legible Partners with Visteon to Expand Global Infotainment Reach

Legible Media Inc

February 15, 2024 – TheNewswire - Vancouver, British Columbia – Legible Inc. (CSE:READ) (OTC:LEBGF) (FSE:D0T) ("Legible”, or the “Company”), a trailblazer in digital content solutions, is proud to announce a strategic partnership with Visteon ( NASDAQ:VC ), to include Legible as part of AllGo, Visteon’s cutting-edge automotive app store. This collaboration marks a significant leap in providing a comprehensive infotainment experience to drivers and passengers, seamlessly integrating audiobooks into the automotive entertainment ecosystem. Visteon’s AllGo App Store provides automakers with leading-edge connected car experiences that can be customized for their customers by brand, model, trim level or even geolocation. A dedicated portal for automakers includes certified apps that are pre-filtered to the countries where the car company operates and gives them full control over which applications they wish to offer through their own customizable platforms. In a move that aligns with the ever-evolving landscape of in-car entertainment, Legible will be the first to offer a vast library of audiobooks through AllGo to drivers and passengers in India and across Asia. This partnership leverages the innovative capabilities of both companies to create a dynamic and immersive content platform for users on the move. "Visteon's AllGo is delighted to partner with Legible to expand our content offerings. This collaboration aligns with our commitment to providing innovative and diverse experiences for users within the automotive ecosystem," said Rishita Bachu, Director of Product Management at Visteon. "Legible is excited to join forces with Visteon's AllGo to bring the world of literature to drivers and passengers. This collaboration underscores our commitment to providing high-quality digital content solutions in the automotive sector," said Kaleeg Hainsworth, CEO of Legible. Key Features of the Partnership: Diverse Digital Library: Users can access a diverse range of audiobooks, catering to various interests and genres, ensuring a personalized and engaging reading experience. Legible Unbound members also get access to millions of ebooks for reading on their devices. Seamless Integration: Legible and Visteon's Allgo are collaborating to ensure a seamless integration of audiobooks into the automotive app store, making it easily accessible for drivers and passengers. Enhanced User Experience: The partnership focuses on delivering an enhanced user experience, combining Legible's expertise in content curation with AllGo's intuitive interface, providing a user-friendly platform for in-car entertainment. As part of the collaboration, Legible's digital publications will be seamlessly integrated into Visteon's AllGo app store, enriching the content portfolio available to drivers and passengers. Users can enjoy their favorite books on the go, transforming their daily commute or road trips into immersive literary experiences. About Visteon Visteon is advancing mobility through innovative technology solutions that enable a software-defined and electric future. With next-generation digital cockpit and electrification products, Visteon leverages the strength and agility of its global network with a local footprint to deliver a cleaner, safer and more connected vehicle experience. Headquartered in Van Buren Township, Michigan, Visteon operates in 17 countries worldwide, recorded approximately $3.76 billion in annual sales and booked $6 billion of new business in 2022. For more information visit visteon.com. About Legible Inc. Legible is a groundbreaking, mobile-centric global company specializing in eBooks and audiobook entertainment, boasting a market opportunity exceeding billions of dollars. Legible’s extensive partnerships encompass four of the Big 5 Publishers and the world's largest eBook distributor, enabling Legible to seamlessly deliver millions of eBooks and audiobooks, effectively transforming any smart device into a dynamic library and eBookstore. At the heart of Legible’s innovation lies its Librarian AI, the world's pioneering AI-powered literary assistant, enhancing the reading experience. Legible’s publishing division is revolutionizing the industry by crafting proprietary AI-enriched multimedia books, setting new standards in literary engagement. Legible is at the forefront of reshaping the digital publishing landscape, committed to gaining a significant market share by providing innovative 21st-century publishing solutions and enriching global reading experiences. Please visit Legible.com and discover the place where literature comes to life. Legible IR Contact Mr. Neil Simon, CEO Investor Cubed Inc. Tel: (647) 258 3310 Email: nsimon@investor3.ca Legible Press Contact Deborah Harford EVP, Global Strategic Partnerships invest@legible.com Website: https://invest.legible.com Visteon Contact media@visteon.com Cautionary Note Regarding Forward Looking Information This Press Release contains certain statements which constitute forward-looking statements or information (“forward-looking statements”), including statements regarding Legible’s business. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Legible's control, including the impact of general economic conditions, industry conditions, currency fluctuations, the lack of availability of qualified personnel or management, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Legible believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward- looking information. As such, readers are cautioned not to place undue reliance on the forward- looking information, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this document are made as of the date of this document and, except as required by applicable law, Legible does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

February 15, 2024 11:30 AM Eastern Standard Time

Image

Proactive Group Holdings Joins Forces with Sevva AI in UK Government-Backed AI Sustainability Initiative

Proactive Group Holdings

Proactive Group Holdings Inc. (“Proactive”), the AI-powered digital stakeholder engagement firm, is pleased to announce its participation in an artificial intelligence pilot consortium backed by the UK government. This initiative, led by Sevva AI, a leading provider of generative AI automation for enterprise, is focused on the acceleration of trustworthy AI tools aimed at meeting critical sustainability goals and improving green revenue targets. Launched earlier this month and expected to extend into 2025, the collaboration will see the introduction of AI tools as early as April. The innovative technology promises to provide corporations and investors with sophisticated AI tools to manage the complex landscape of ESG investing mandates. The selection of Proactive as a project member follows Sevva AI's receipt of a £500,000 grant from Innovate UK, the UK Government Innovation agency that backs projects that enhance economic growth and productivity. The grant will partially fund the development of Generative AI tools aimed at sustainability assessment, with Sevva AI providing the other half of the required project funding. Emanuela Vartolomei, Sevva founder and Chief Executive, said: “Proactive was chosen for this project for being an early adopter of AI, demonstrating a keen interest in leveraging technology to enhance its sustainability footprint. If you have ambition to go beyond your peer group, you need a boost from AI.” Ian Mclelland, Chief Executive of Proactive, added: “We are delighted to be part of this ground-breaking project. It aligns perfectly with our internal efforts and the launch of our NewsifAI™ platform, our suite of writing and editing tools which has streamlined our news production process. We look forward to working alongside the Sevva team.” On February 5, Proactive unveiled the integration of artificial intelligence within its operations, marking a significant increase in content production capabilities for its financial news platform, Proactive Investors. This strategic advancement is centered around the development and deployment of bespoke generative pre-trained transformers (GPTs) within its proprietary NewsifAI™ editorial platform. About Proactive At Proactive, our mission is to provide best-in-class AI-powered digital solutions to companies across the globe seeking to improve engagement with their stakeholders. Our products deliver media support, corporate websites, engagement analytics, and shareholder tools for publicly listed issuers. Our purpose is to help companies improve their communication and engagement with their shareholders, stakeholders, and the broader investment community. Proactive provides solutions to almost 2,000 companies in Australia, Canada, UK, and the USA. For more information, click here. About Sevva AI www.sevva.ai is a leading provider of NLP and generative AI automation for tier-1 financial institutions and corporations. Sevva provides enterprise-grade automation of key workflows including research, investment and lending processes, sustainability and corporate reporting, regulatory alignment and investor relations. Sevva AI brings to organizations the unique opportunity to explore, test, and integrate AI Agents, Co-Pilots, and Chatbots into their workflows with ease. Contact Details Craig Ribton, Corporate Development Director +44 20 7989 0813 investors@proactiveinvestors.com Company Website https://www.proactive.inc

February 15, 2024 10:12 AM Eastern Standard Time

Investments & Wealth Institute Introduces New RMA® Program Offering with Chicago Booth School of Business

Investments & Wealth Institute

The prestigious Retirement Management Advisor® Certification can now be completed at the University of Chicago Booth School of Business as part of the immersive Chicago Booth RMA® Capstone experience. In partnership with The University of Chicago Booth School of Business — ranked the No. 1 Best Business School by the US News & World Report in 2023-2024 — the Institute’s RMA Certification program offers strategies and practical tools to build custom retirement income plans, mitigate clients' risks, and master the retirement planning advisory process. Designed specifically for today’s leading retirement professionals, this program’s cutting-edge curriculum will empower advisors with elevated, specialized capabilities, helping to differentiate their practices in a crowded and growing marketplace. The RMA® Capstone is a core component of the RMA® Certification program, and may be completed entirely online, or as part of a two-day, in-person executive education experience on the campus of the Chicago Booth School of Business. While onsite, candidates will have direct access to top industry practitioners and academic experts, including Clinical Associate Professor of Strategic Management, Kathleen Fitzgerald, and Merle Erickson, Ph.D., distinguished Professor of Accounting. “Chicago Booth is extremely proud to administer both the Retirement Management Advisor certification curriculum and the RMA® Capstone experience for today’s most successful retirement advisors,” said Mark Lewis, Executive Director of Executive Education at The University of Chicago Booth School of Business. “Our partnership with the Institute already runs deep, teaching advanced curriculums for the Institute’s industry leading CIMA® and CWPA® certifications, and the addition of the RMA® program completes a world-class triumvirate.” Advisors accepted into this cohort will be eligible to attend the onsite Chicago Booth RMA® Capstone experience in downtown Chicago from October 9-10, 2024. Taking place at the Gleacher Center on the Chicago Booth campus, this two-day education and test-prep symposium will culminate with the RMA® Certification Exam on October 10. “Today’s professional retirement management advisors are staring at a truly generational business opportunity. Mass-affluent and high-net-worth Baby Boomers are already retiring in enormous numbers, and this trend will only gain momentum as the next two decades unfold,” said Mike Kurz, Director of Programs at the Investments & Wealth Institute. “Therefore, the exceptional advisor will be looking to position themselves with the practical knowledge and skills to expertly serve this quickly expanding market — but also to achieve industry acclaimed designations and credentials that will help them differentiate and successfully market their retirement management expertise. The RMA® certification with Chicago Booth’s executive education experience provides exactly what these motivated entrepreneurs will need to compete successfully in the future.” Registration is now open. Interested advisors must complete their RMA® application by April 1, 2024 to take part in the 2024 Capstone offering at Chicago Booth. All advisors accepted into the upcoming RMA® cohort will experience a foundational, five-month intensive executive education program, beginning in May 2024. The core curriculum offers guided self-study modules of on-demand readings, recorded lectures, case studies, analysis with worksheets, use of a specialized financial calculator, and periodic sectional quizzes. The RMA® program teaches proficiency and excellence in retirement planning, including the management of the decumulation life stage, which is a critical need for many clients. It also increases proficiency in building custom retirement income plans through holistic discussions and discovery processes that reflect a client’s unique retirement situation. To be certified, candidates are also required to meet a three-year experience threshold, pass a comprehensive background check, complete online education modules, and pass a 115-question certification examination. Interested parties can learn more about the RMA ® Certification program here and can apply for the program online. An introductory webinar is available here. Private cohorts for corporate clients are also available; please contact Kari Estes at kestes@i-w.org for information. Learn more about the new RMA® Capstone program here. About Investments & Wealth Institute Founded in 1985, the Investments & Wealth Institute is the premier professional association, education provider, and standards body for financial advisors. Through its award-winning events, publications, courses, and acclaimed certifications — Certified Investment Management Analyst® (CIMA®), Certified Private Wealth Advisor® (CPWA®), and Retirement Management Advisor® (RMA®) — the Institute delivers Ivy League-quality, highly-practical education to more than 30,000 practitioners annually in over 40 countries. Members of the Institute include the industry's most successful investment consultants, advanced financial planners, and private wealth managers who embrace excellence and ethics in applying a broad set of knowledge and skills in their daily work with clients. Learn more at https://investmentsandwealth.org/. About The University of Chicago Booth School of Business The University of Chicago Booth School of Business has a long history of groundbreaking advancements that have revolutionized the financial industry. Chicago Booth is home to ten Nobel laureates who have helped define the study of economics and the nature of today’s financial markets — including 2013 recipient Eugene F. Fama, widely recognized as the “father of modern finance,” and 2017 recipient Richard H. Thaler, a “founding father” of behavioral economics. Chicago Booth is the alma mater of countless alumni in the investment management industry — making it the ideal setting for financial professionals who want to elevate their understanding of investment management and portfolio construction, gain access to renowned faculty and industry experts, and expand their clientele. Chicago Booth has campuses in Chicago, London, and Hong Kong. Learn more at https://www.chicagobooth.edu/executiveeducation. Contact Details Allison Edmondson +1 303-850-3207 aedmondson@i-w.org Company Website https://investmentsandwealth.org

February 15, 2024 10:00 AM Eastern Standard Time

[Video Enhanced] Dolly Varden Silver (DV.V) is now officially in the gold business

Dolly Varden Silver Corporation

February 15, 2024 – TheNewswire – Global Stocks News – On February 12, 2024 Dolly Varden Silver (TSXV:DV) (OTC:DOLLF) published assay results from its 2023 step-out drilling program at the Homestake Ridge property. DV intersected a new gold-rich zone, to the northwest from the Homestake Silver Deposit. DV Silver is developing its 100% held Kitsault Valley Project located in the Golden Triangle of British Columbia, Canada, 25 kilometers by road to tide water. It also has a new consolidated copper-gold porphyry project in the Golden Triangle, similar to other deposits in the region (Red Mountain, KSM, Red Chris). Highlights of Homestake Silver step-outs to the northwest include: (intervals shown are core length**) HR23-389: 79.49 g/t Au and 60 g/t Ag (80.21 g/t AuEq*) over 12.45 meters including 1,335 g/t Au*** and 781 g/t Ag (1,344.42 g/t AuEq*) over 0.68 meters within a broad mineralized zone grading 15.26 g/t Au and 20.05 g/t Ag (15.50 g/t AuEq*) over 66.50 meters. HR23-399: 43.10 g/t Au and 66 g/t Ag (43.90 g/t AuEq*) over 1.01 meters and 40.33 g/t Au and 418 g/t Ag (45.37 g/t Au Eq**) over 1.75 meters within a broad mineralized zone grading 2.68 g/t Au and 20 g/t Ag (2.92 g/t AuEq*) over 57.70 meters. HR23-410: 10.17 g/t Au over 6.61 meters including 50.70 g/t Au over 0.62 meters Highlights from Homestake Main infill drilling below high-grade plunge include: (intervals shown are core length**) HR23-374: 22.60 g/t Au over 0.67 meters, 18.75 g/t Au over 2.00 meters and 10.15 g/t Au over 1.00 meter in separate vein breccias included in a wider mineralized envelope grading 1.22 g/t Au and 1.90 g/t Ag (1.24 g/t AuEq*) over 83.51 meters. HR23-386: 18.14 g/t Au and 30 g/t Ag (18.51 g/t AuEq*) over 2.50 meters including 69.9 g/t Au and 42 g/t Ag (70.41 g/t AuEq*) over 0.50 meters. HR23-390: 129.00 g/t Au and 218 g/t Ag (131.63 g/t AuEq*) over 0.50 meters in a vein breccia included in a wider mineralized envelope grading 1.92 g/t Au and 3.58 g/t Ag (1.96 g/t AuEq*) over 50.30 meters. *AuEq and AgEq are calculated using $US1650/oz Au, $US20/oz Ag **Estimated true widths vary depending on intersection angles and range from 50% to 85% of core lengths. ***Determined using metallic screen fire assay on 1.0 kg split Click Image To View Full Size On February 13, 2024, Dolly Varden Silver CEO Shawn Khunkhun discussed the February 12 news with CEO.ca on-air host, Amrit Gill. [1] “These results represent a brand-new gold zone,” Khunkhun confirmed to Gill. “If you go to the Homestake Ridge part of the property, there are two dominant zones Homestake Main and Homestake Silver. There's about 350 meters that separate the two zones”. “One is a silver zone with gold. The other is a gold dominant deposit. We've just tagged a very high-grade gold area,” continued Khunkhun. “This represents a 50-meter step out. The closest data point is 75 meters away. So, it's a significant step out. As we look ahead at the next round of drilling, we're going to want to see how big this zone is.” "The new high-grade gold and silver mineralization encountered in step out drilling to the northwest of Homestake Silver represents a significant breakthrough in further defining, upgrading and expanding the mineralization at Homestake Ridge," confirmed Rob van Egmond, Vice-President Exploration." This new zone remains open to the northwest, projecting towards the Homestake Main Deposit." The February 12 press release includes the remaining drill results from 48 drill holes from the 2023 drill program at the 100%-owned Kitsault Valley Project. This includes 26 drill holes at Homestake Main (11,054.90 meters ), four drill holes (2,478.00 meters) from the new gold-rich zone at the Homestake Silver northwestern extension, and six exploration drill holes on the Homestake Ridge property (1,627.00 meters). In addition, twelve holes (6,971.00 meters) from the Dolly Varden property including the North Star, Red Point and Wolf areas were also reported in the release. In the last 6 years, there has been significant M&A activity in The Golden Triangle. Click Image To View Full Size On November 2, 2023 Dolly Varden Silver announced that it has closed a deal where Hecla Canada invested $10 million in DV Silver, raising its stake in DV Silver from 10.6% to 15.7%. Hecla Mining has a market cap of USD $2.08 billion and trades on the New York Stock Exchange (NYSE). It produced 14.2 million ounces of silver in 2023. “We have this new North American focus,” Hecla CEO Phillips J. Baker told Kitco Mining on January 26, 2024. “T o the extent we can continue to grow in the US and Canada, we'll certainly do that. You can see that with our investment in Dolly Varden Silver.” “Hecla has demonstrated it is a sticky shareholder,” Khunkhun confirmed to Global Stocks News CEO, Guy Bennett. “They're looking to expand their North American silver portfolio.” Click Image To View Full Size Source: https://twitter.com/peter_krauth/status/1725536566527795706/photo/1 “Global silver demand is forecast to reach 1.2 billion ounces in 2024, which would mark the second-highest level on record, the Silver Institute said in a recent report,” according to CNBC. “We think silver will have a terrific year, especially in terms of demand,” Michael DiRienzo, executive director of the Silver Institute told CNBC. He expects silver prices to reach $30 per ounce, which would be a 10-year high, according to data from LSEG.” “The institute sees a 9% climb in demand for silverware and a 6% rise in jewelry demand this year,” reported CNBC, “with India expected to drive the jump in jewelry purchases. A projected recovery in consumer electronics is also poised to give the silver market an additional boost, the report stated.” "Whether we discover new zones of high-grade gold at Homestake Ridge or expand the large, wide and high-grade silver deposits at Wolf and Torbrit, drilling continues to deliver results from the premier, undeveloped gold-silver trend in Canada," stated Khunkhun in the February 12, 2024 press release. References: [1] CEO.ca is a part of the media portfolio of EarthLabs, which includes The Northern Miner, Canadian Mining Journal and Mining.com. CEO.ca has over 9 million users and 18 million monthly page views Contact: guy.bennett@globalstocksnews.com Full Disclaimer

February 15, 2024 09:42 AM Eastern Standard Time

Video Image

N6 Powered by KRMA Announces Acquisition of West of Fairfax

N6 Powered by KRMA

N6 Powered by KRMA (N6KRMA), an AI-powered digital marketing and communications agency, today announced its acquisition of boutique digital marketing agency West of Fairfax. Headquartered in Los Angeles, CA, West of Fairfax specializes in bespoke approaches to digital marketing reinforced by over a decade of experience partnering with global clients, including Selena Gomez, Bliss, Cincoro, COOLA, Dee Ocleppo, and more. The company provides a boutique, tailored experience for its clientele that achieves goals by establishing strong brand identities through collaborative partnership. Through the acquisition, West of Fairfax will continue to offer its thoughtful strategy and innovative storytelling approach while elevating the company to new heights. Founded six years ago by Courtney Lopez, Ryan Good, and Ray Lee, West of Fairfax began with its deep roots in social media. Today, the company is led by founder, Chief Executive Officer Courtney Lopez, and her all-female-powered team. West of Fairfax offers content creation, platform management, platform strategy, influencer programming, paid advertising, customized analytics & reporting, and more. With the added strategic support and merged resources of the N6KRMA team, Lopez aims to provide expert and expanded client services while creating unprecedented growth opportunities for the world-class West of Fairfax team. "We are thrilled to take this next step with N6 Powered by KRMA," says Courtney Lopez, Founder of West of Fairfax. "I always knew that we’d need a strategic partner to take the next step as an agency, and after many conversations and much consideration, the perfect fit came to us through N6KRMA; a partner that shares the same vision and standard of excellence for both clients and team members. This collaboration opens doors to many new and exciting possibilities with our expanded resources and a much wider offering of services. It also allows for a new level of care and possibility for the incredible women on our team, of whom I am very proud. The future feels very bright.” The acquisition reflects N6 Powered by KRMA’s commitment to creating a fully integrated offering for clients that combines public relations expertise, technology, cutting-edge digital marketing, and creative strategies. Launched in August 2023, N6KRMA was formed by merging leading AI-enabled marketing technology company KRMA with world-class public relations and marketing firms N6A and Studios. N6 Powered by KRMA brings together the best minds, clients, and capabilities to redefine marketing and public relations as many move into an increasingly data-centric marketplace. Morgan Harris, CEO of North Sixth Group, the parent company of N6 Powered by KRMA, shares Lopez’s excitement for the future: "I am truly excited by our partnership with West of Fairfax. This collaboration marks a significant milestone for N6KRMA, and together, we are poised to shape the future of our industry and deliver unparalleled services to our clients." To learn more about N6 Powered by KRMA and West of Fairfax, please visit N6KRMA.com and Westof.co. About West of Fairfax West of Fairfax promotes a personal, individualized experience that achieves your goals while establishing a strong brand identity and positive brand association. Thoughtful strategy and innovative storytelling are reinforced by more than a decade of experience partnering with global clients. About N6 Powered by KRMA At N6 Powered by KRMA, the ultimate marketing powerhouse comes to life through the seamless integration of public relations, AI, and an exceptional creative team. With unmatched expertise and proprietary AI technology, N6 Powered by KRMA empowers leading global brands to achieve remarkable marketing outcomes. By harmonizing the analytical brilliance of AI with the artistry of public relations and creative campaigns, N6 Powered by KRMA offers solutions that ensure clients thrive in the ever-evolving data-oriented marketing landscape. N6 Powered by KRMA was formed by merging leading AI-enabled marketing technology company KRMA with world-class public relations and marketing firms N6A and Studios. N6 Powered by KRMA is wholly owned and operated by North Sixth Group, a family office operating company with interests in media, marketing, technology, and sports and entertainment businesses. Contact Details N6 Powered by KRMA Jacky Agudelo jacky.agudelo@n6krma.com

February 15, 2024 09:00 AM Eastern Standard Time

BENZINGA Presents a Special Virtual Event: “Mining Unearthed: Navigating the Ore of Innovation”

Benzinga

Benzinga, a leading financial media company, is thrilled to announce its upcoming virtual event on February 15, 2024: " Mining Unearthed: Navigating the Ore of Innovation ". Discover the untold opportunities within the metals & mining industry, often overlooked by investors. Join us for an enlightening webinar that delves into the vital role of Metals & Mining in 2024 and how it shapes global economies. Gain valuable insights to optimize your investment strategies and harness the full potential of this dynamic sector for your portfolio’s success. Don’t miss out on unlocking the hidden gems of Metals & Mining investing! This event takes place on Thursday, February 15, 2024, at 11 AM EST. It is free to attend. Event Details: Title: Mining Unearthed: Navigating the Ore of Innovation Date: February 15, 2024 Time: 11:00 AM EST Registration page: https://www.benzinga.com/events/mining-unearthed-2024/ Featured Speakers: Dennig Higgs, President of Austin Gold Corp. Miles Rideout, VP of Exploration of Argentina Lithium & Energy Corp. Taylor McKenna, Analyst at Kopernik Global Investors Brett Richards, CEO & Director of Goldshore Resources This event is free of charge, providing an excellent opportunity for investors, both experienced and novice, to gather valuable insights from industry leaders at no cost. Registration Information: To secure your spot and optimize your real estate investment strategy, click this registration link. For media inquiries, please contact: Benzinga Media Relations Email: drew@benzinga.com Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 15, 2024 08:40 AM Eastern Standard Time

Apex Trader Funding Crosses $100 Million Paid To Its Traders

Apex Trader Funding

By Austin DeNoce, Benzinga Apex Trader Funding has made its mark in the day trading arena, offering an array of benefits and packages tailored to the needs of modern traders interested in expanding their capabilities. With a focus on flexibility and empowerment, Apex provides a unique platform for traders looking to take control of their financial futures and push their profits to new heights through its trader evaluation and capitalization strategies. Apex's Impact On Trader Compensation Apex Trader Funding has gained a name in trader compensation since 2022, averaging about $7 million monthly since January 2023 and exceeding $35 million in total payouts over the past 90 days. From 2022 to the present day, Apex has paid more than $100 million to its traders, demonstrating its commitment and potential to offer substantial opportunities. The platform stands out with its flexible qualification criteria, allowing traders to become eligible in as little as seven trading days. Its no-daily-drawdown policy, coupled with the risk monitoring capabilities of its rTrader software, adds to its trader-friendly environment. Apex also facilitates trading 23 hours a day, including holidays and during major news events. It only requires that trades be closed before 4:59 PM EST. With a variety of contracts accommodating different risk levels and trading styles and features like NinjaTrader licenses and real-time data fees, Apex caters to diverse trader needs. The platform's compatibility with various trading software and its accessibility across multiple devices further enhance its appeal. Apex not only provides traders with essential trading tools and information on a wide range of financial instruments but also offers a dynamic and supportive environment for managing and growing their trading portfolios. Here are some of the specific advantages Apex provides traders: Generous Compensation: 100% of the first $25,000 per account and 90% thereafter. Regular Payouts: Two monthly payouts for consistent earnings access. Quick Qualification: Qualify in as little as 7 days. Flexible Trading: Full-sized contract trading with no scaling or over-contract penalties. No Daily Drawdowns: Stress-free trading without daily loss limits. Holiday and News Trading: Trade anytime, including holidays and news events. Unlimited Earnings: No cap on maximum payouts. Streamlined Evaluation: Efficient one-step entry process. Robust Trading Support: Real-time data, simple risk rules and software compatibility. Multi-Account Management: Handle up to 20 accounts at once. “The Trader Bacon Show” For a deeper insight into the real-world impact of Apex Trader Funding, “ The Trader Bacon Show ” on YouTube offers an invaluable resource. Hosted by Gates W. Adams, the show features discussions with successful futures traders who have utilized Apex's platform to enhance their trading careers. These traders share their strategies, experiences and insights, offering viewers a practical perspective on the advantages of trading with Apex. Feedback From The Trading Community Apex Trader Funding has earned high acclaim on Trustpilot, securing a five-star rating from 93% of its reviewers. This overwhelming approval is a testament to the platform's effectiveness in meeting trader needs. Reviewers consistently praise Apex for its speedy service, excellent customer support and straightforward evaluation process. Traders particularly value the transparency and fairness of Apex's rules, highlighting its role in providing affordable access to funded accounts. The firm's efficiency in processing payments and offering attractive discounts has also garnered positive remarks. Many express gratitude for the opportunities Apex has provided for their trading pursuits, noting its significant impact on their trading journeys. While feedback is predominantly positive, some minor critiques mention challenges in navigating specific rules and addressing payment selection errors. But overall, Apex Trader Funding is recognized as a reliable and supportive trader evaluation firm committed to aiding traders' success. A Platform For Aspiring And Experienced Traders Alike Apex Trader Funding offers a unique blend of flexibility, support and financial opportunities for traders, and through its user-friendly platform, transparent rules and generous compensation, it’s well-equipped to support both aspiring and experienced traders. Whether you're looking to start your trading journey or take your skills and profits to the next level, Apex provides the tools and environment to help you achieve your goals. Explore your trading potential with Apex Trader Funding today. Featured photo by Celyn Kang on Unsplash. We are a community of traders. We believe in helping traders trade well with over 60,000 members across the globe since 2021. RISK DISCLOSURE: This is not an investment opportunity. You do not deposit any funds for investment. We do not ask for any funds for investment. At no time do you risk your own capital. There are no promises of rewards or returns. HYPOTHETICAL PERFORMANCE DISCLOSURE: Hypothetical performance results have many inherent limitations, some of which are described below. No representation is being made that any account will or is likely to achieve profits or losses similar to those shown. In fact, there are frequently sharp differences between hypothetical performance results and the actual results subsequently achieved by any particular trading program. One of the limitations of hypothetical performance results is that they are generally prepared with the benefit of hindsight. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. For example, the ability to withstand losses or to adhere to a particular trading program in spite of trading losses is material points, which can also adversely affect actual trading results. There are numerous other factors related to the markets in general or to the implementation of any specific trading program, which cannot be fully accounted for in the preparation of hypothetical performance results and all of which can adversely affect trading results. Testimonials appearing on this website may not be representative of other clients or customers and are not a guarantee of future performance or success. AVAILABLE INSTRUMENTS: Apex Trader Funding customers are allowed to only trade Futures products, listed on the following exchanges: CME, COMEX, NYMEX & CBOT. Trading of Spot Currencies, CFD's Stocks, Options, and Cryptocurrencies are not permitted or available in our programs vendors or platforms. EVALUATION DISCLAIMER: The customer pass rate of the evaluation program was 43.13% between January 1, 2023 â Sept 1, 2023, who traded at least one evaluation and obtained a PA Account during this time period. The Evaluation and PA are meant to be as close to a realistic simulation of trading under actual market conditions, including commissions, to mimic real market conditions, and the evaluation is difficult to pass even for experienced traders. The event is not meant to train the customer to be better but to be a challenge to pass. The Evaluation is not suggested for individuals with little to no trading experience. CUSTOMER COMPENSATION DISCLOSURE: All trades presented for compensation to customers should be considered hypothetical and should not be expected to be replicated in a live trading account. PA Accounts may represent simulated accounts or live or copied accounts. Testimonials and payouts appearing on this website may not be representative of other clients or customers and are not a guarantee of future performance or success. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Cameron Nish cameron@apextraderfunding.com Company Website https://apextraderfunding.com

February 15, 2024 08:30 AM Eastern Standard Time

Image

Candel Therapeutics Sets Stage For Success With Cancer-Fighting Immunotherapies

Candel Therapeutics

By Jeremy Golden, Benzinga A clinical-stage biopharmaceutical company looks forward to the year ahead with several promising developments in motion. Focused on the development of multimodal biological immunotherapies to help patients fight cancer, Candel Therapeutics, Inc. (NASDAQ: CADL) is innovating a new frontier in the field of immunotherapy. By leveraging a data-driven approach, the company seems poised to advance next-generation immunotherapies in its pipeline as well as create new product candidates. Following up on promising initial clinical and biomarker data in hard-to-treat cancers, Candel is moving forward with a focus on strategic key value drivers and catalysts. Lead Candidates Based in Needham, Massachusetts, Candel is developing two off-the-shelf clinical-stage investigational viral immunotherapies. Designed to elicit an individualized anti-cancer response, they are based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. It’s in the midst of ongoing late-stage clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2) and localized, non-metastatic prostate cancer (phase 2 and 3). CAN-3110 is the lead product candidate from the HSV platform. A phase 1 clinical trial in recurrent high-grade glioma (HGG) is currently ongoing. Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform that leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors. The year 2023 was a productive one for Candel. The company received Fast Track Designation from the FDA based on encouraging clinical activity and biomarker data from the phase 2 clinical trial of CAN-2409 in NSCLC, was also granted Fast Track Designation based on the positive interim data from the ongoing randomized phase 2 clinical trial in borderline resectable pancreatic cancer, published the activity of CAN-3110 in recurrent high-grade glioma in Nature and presented data on the first molecule that was discovered based on the enLIGHTEN TM Discovery Platform at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). In NSCLC, the phase 2 clinical trial showed that experimental therapy with CAN-2409 achieved disease control in most of the patients who had an inadequate response to immune checkpoint inhibitor treatment. Importantly, there was an abscopal effect (improvement of uninjected lesions) in most patients with metastatic disease. There was an increase in effector/cytotoxic T cells and natural killer cells in peripheral blood after the second CAN-2409 administration (the booster), which was linked with subsequent improved survival. Candel reports that it has observed an encouraging number of long survivors, which the company believes demonstrates that CAN-2409 may induce a new state of functional immunosurveillance and durable disease control. The gold standard endpoint in this population is overall survival. Based on the currently available treatments, median overall survival ≥ 14 months will be considered a significant improvement compared to standard of care. Candel also reported positive interim data from a randomized, controlled clinical trial that revealed a notable increase in survival in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) after experimental treatment with CAN-2409 plus standard-of-care treatment compared to standard-of-care control treatment alone. The estimated overall survival rate was 71.4% at 24 months in CAN-2409 treated patients versus 16.7% in the control arm after chemoradiation. In patients with progressive disease, there was both a CA19-9 (tumor biomarker) and a survival response to salvage chemotherapy in the CAN-2409 arm but not in the control arm. Dense aggregates of immune cells were observed in PDAC tissue after CAN-2409 treatment, confirming the activation of a robust antitumoral immune response in this immunosuppressive form of cancer. “In 2023, we received Fast Track Designation for both NSCLC and pancreatic cancer, a validation from the FDA on the potential of CAN-2409, our most advanced product candidate,to address these unmet medical need cancers,” said Paul Peter Tak, MD PhD FMedSci, President and CEO of Candel. “Clinical data from the ongoing phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma have recently been published in Nature, serving as further recognition of the scientific and clinical excellence of Candel’s programs.” Candel and collaborators at the Brigham and Women’s Hospital published in the high-impact journal Nature that CAN-3110 was well tolerated with no dose-limiting toxicity reported. The investigators observed a nearly doubling of the expected median overall survival after just a single injection of CAN-3110 when compared to expected survival in patients treated with current chemotherapeutic standards of care. Positive HSV-1 serology was a predictor of response and was associated with improved survival. Furthermore, increased infiltrating immune cells in the tumor microenvironment and expansion of the T cell repertoire after treatment were associated with improved survival. Importantly, these results were seen after a single injection of CAN-3110; Candel and its collaborators are currently evaluating a multiple-injection regimen, supported by the Break Through Cancer foundation. “The data generated with CAN-3110 in recurrent high-grade glioma represents a significant step forward in the development of groundbreaking therapeutic candidates for this difficult-to-treat disease,” said Francesca Barone, M.D. PhD, CSO, at Candel Therapeutics. “At the same time, they provide proof of concept for the expansion of CAN-3110 in other Nestin positive tumors, which include a diverse spectrum from triple negative breast cancer to melanoma to soft tissue sarcoma.” What’s To Come Backed by promising clinical and biomarker data in hard-to-treat indications, the company expects six data readouts across three platforms this year, including overall survival data in NSCLC and topline data of the potentially registrational phase 3 clinical trial in prostate cancer. Those data readouts include: Topline overall survival (OS) data for CAN-2409 in a phase 2 topline trial for NSCLC in Q2 2024 Updated overall survival data for CAN-2409 in a phase 2 trial for borderline resectable pancreatic cancer in Q2 2024 New data on the second drug candidate from the enLIGHTEN Discovery Platform by Q3 2024 Phase 1 data for CAN-3110 in recurrent high-grade glioma in 2H 2024 for the multiple injection cohort Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer in Q4 2024 Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer in Q4 2024 During the SITC Annual Meeting and the International Oncolytic Virus Conference (both in 2023), Candel presented the first experimental candidate from enLIGHTEN Discovery Platform Alpha 201-macro-1, an investigational, locally-delivered biological oncolytic therapeutic designed to interfere with the CD47/SIRP1a pathway which demonstrated better inhibition of tumor growth when compared to systemic anti-CD47 antibody therapy in a mouse model of breast cancer. Francesca Barone, M.D. PhD, said “With the enLIGHTEN Discovery Platform, we are leveraging our internal capabilities in advanced analytics, cancer biology and vectorology to design a new class of multimodal therapeutics that can overcome mechanisms of resistance present in the tumor microenvironment.s “This platform is open for collaborations with external partners as illustrated by our collaboration with U Penn aimed at designing a viral gene construct able to support the therapeutic efficacy of CAR-T therapy in pancreatic cancer.” Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. This article includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, and strategic plans for the Company’s business and product candidates, and other risks identified in the Company’s SEC filings, including the Company’s most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Aljanae Reynolds +1 617-916-5445 areynolds@wheelhouselsa.com Company Website https://www.candeltx.com/

February 15, 2024 08:25 AM Eastern Standard Time

Cardio Diagnostics (NASDAQ: CDIO) Expands Partnership With Family Medicine Specialists To Bring Specialty Cardiology Tests To Select Walmart Supercenters

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga A precision cardiovascular medicine company’s innovative AI-driven epigenetic-genetic blood tests will soon be available in one of the nation’s largest retailers. Beginning Q2 2024, Cardio Diagnostics (NASDAQ: CDIO) will bring its advanced blood-based epigenetic-genetic tests, Epi+Gen CHD and PrecisionCHD, to the Walmart Supercenter in Round Lake Beach, Illinois. The northern suburb of Chicago has been chosen as the strategic starting point for a new retail healthcare initiative, the company said. The initiative is an expansion of the ongoing Heart Attack Prevention Initiative, a partnership with Family Medicine Specialists (FMS). With the launch of the Heart Attack Prevention Initiative, FMS started deploying Epi+Gen CHD in at least 1,200 patients with coronary heart disease (CHD) risk factors across its BlueCross BlueShield Medicare, Medicaid, HMO and PPO health plans. According to the company, this partnership benefits both patients and providers through early heart attack risk prevention, in addition to offering significant value to health plans. By leveraging Cardio Diagnostics’ technology, FMS is increasing the accessibility of clinical cardiovascular diagnostic solutions, moving them beyond traditional provider settings and into the more accessible realm of retail healthcare for hundreds of additional patients in Lake County, Illinois. “Our partnership with FMS to bring our tests to their Walmart locations is a game-changer in the field of cardiovascular health management,” said Meesha Dogan, Ph.D., Co-Founder and CEO of Cardio Diagnostics. “By integrating Cardio Diagnostics’ state-of-the-art clinical tests within FMS’s expansive retail network, we are shifting the paradigm from a model that relies on specialty care infrastructure to one that meets American communities in their backyard. This strategic alliance not only democratizes access to top-tier heart disease services but also propels Cardio Diagnostics as a leader in cardiovascular retail healthcare innovation. Our ultimate goal is to meet patients where they are, weaving advanced medical services seamlessly into the fabric of their everyday lives.” Accessibility The retail healthcare footprint and market share continue to grow as more Americans embrace the convenience and accessibility of high-quality healthcare services. In their most recent report, AMN Healthcare reported that 30.3% (79.6 million) Americans received care at a retail clinic. About 32.8% of Americans are forecasted to do so in 2024. At the Round Lake Beach Walmart location of FMS, walk-ins will have access to both of Cardio Diagnostics’ clinical blood tests. The company’s epigenetic-genetic cardiovascular clinical blood tests, Epi+Gen CHD and PrecisionCHD detect heart attack risk and coronary heart disease status, respectively. These tests are easy to administer in the retail healthcare setting because they only require a simple blood draw, bringing this vital service closer to patients. “At Family Medicine Specialists, we have multiple retail healthcare partnerships and are particularly excited about our unique and innovative partnership with Cardio Diagnostics, a leader in clinical cardiovascular diagnostic solutions. This collaboration will enable us to bring advanced cardiac diagnostic tools directly into our retail healthcare clinic locations, enhancing our ability to provide more advanced patient care without the need for additional infrastructure,” Jason Bellucci, MBA, President of Family Medicine Specialists, said. “We believe that this partnership will empower our clinicians with additional resources to better serve our patients’ needs.” Bringing Precision Cardiovascular Testing To Each Neighborhood Heart attacks and coronary heart disease pose significant health risks, and earlier detection and intervention remain crucial for prevention. In the current healthcare paradigm, accessing specialized tests for assessing heart attack risk or diagnosing coronary heart disease means having to navigate complex schedules and significant wait times. While primary care and family medicine practices have managed to maintain relatively shorter waits, specialty areas like cardiology have seen a significant rise, with the average wait time now extending to about 26.6 days. This delay particularly impacts cardiology patients, where timely intervention can be crucial. With 45% of Americans projected to have some form of cardiovascular disease by 2035, the key question is: how can Americans and their providers quickly gain clarity about a patient’s heart disease without weeks of waiting for a specialist appointment? One answer is that cardiology specialty tests must be routinely and readily available in community settings, such as retail healthcare stores. With the deployment of Cardio Diagnostics’ advanced blood tests across select Walmart locations, the company strives to alleviate the critical issue of increasing wait times for specialty care. Beginning with the Round Lake Beach location, expansion to other Walmarts is a key opportunity to reduce wait times for cardiac assessments and care, furthering community-based access to heart disease solutions. The company intends to continue its pursuit of providing organizations with a strong retail healthcare presence and desire to enhance their existing heart disease-related services with precision cardiovascular diagnostic and risk assessment technologies. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

February 15, 2024 08:20 AM Eastern Standard Time

All Industries